Fujian Wanchen Biotechnology Group: Half-year report for the year 2024.
Fujian Wanchen Biotechnology Group: Summary of Half-Year Report in 2024.
Wanchen Group: The number of bulk snack stores exceeded 6,600 in Q2, with a slight increase in net margin compared to the previous quarter. Interpreting the financial report.
1. In the first half of the year, the company's revenue increased by 392.45% year-on-year, with revenue of 10.674 billion yuan from the snack retail business, a year-on-year increase of 447.78%; 2.During the reporting period, the company's "Want Want" brand snack stores increased by a net of 1912 stores, resulting in a total of 6638 stores at the end of the period; 3. Along with the expansion of the snack retail business, the company incurred sales expenses of 0.491 billion yuan in the first half of the year, a year-on-year increase of 331.82%.
Wanchen Group (300972.SZ): The net income in the first half of the year was 0.9346 million yuan, turning losses around year-on-year.
On August 16th, Gelunhui reported that Wanchen Group (300972.SZ) had released its 2024 interim report, with a revenue of 10.915 billion yuan, a year-on-year increase of 392.45%, and a net profit attributable to shareholders of the listed company of 0.9346 million yuan, which turned from a loss to a profit year-on-year. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was -3.0812 million yuan. The basic EPS was 0.0057 yuan.
Wanchen Group (300972.SZ) granted 0.77 million shares of Class II restricted stocks at a grant price of 15.17 yuan/share.
Wanchen Group (300972.SZ) has issued an announcement regarding the 2024 third interim shareholders' meeting resolutions ...
Wanchen Group (300972.SZ) plans to acquire 49% equity of Nanjing Wan Hao for 0.294 billion yuan.
Wanchen Group (300972.SZ) announced that the company plans to acquire Xinghua with its own funds of RMB 294 million.
Here's Why Fujian Wanchen Biotechnology Group (SZSE:300972) Has A Meaningful Debt Burden
Fujian Wanchen Biotechnology Group: Fujian Wanchen Biotechnology Group Co., Ltd.'s performance forecast for the first half of 2024.
Fujian Wanchen Biotechnology Group Co., Ltd.'s (SZSE:300972) Subdued P/S Might Signal An Opportunity
Be Wary Of Fujian Wanchen Biotechnology Group (SZSE:300972) And Its Returns On Capital
Snack discount leader's profit inflection point has arrived | Insight Research
Wanchen Group's net profit for the third quarter was positive, and the net interest rate increased for four consecutive quarters.
Wanchen Group (300972.SZ) announced first-quarter results, net profit of 6.2382 million yuan, a decrease of 88.15%
According to the Zhitong Finance App, Wanchen Group (300972.SZ) released its report for the first quarter of 2024. The company's revenue was 4.83 billion yuan, an increase of 534.03% over the previous year. Net profit attributable to shareholders of listed companies was 6.2382 million yuan, a year-on-year decrease of 88.15%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 1.98,800 yuan, a year-on-year decrease of 96.17%. Basic earnings per share were $0.0388.
Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Wanchen Group (300972.SZ) announced its 2023 annual results, changing profit to loss to 82.965 million yuan
Wanchen Group (300972.SZ) released its 2023 annual report. The company's revenue was 9.294 billion...
Wanchen Group (300972.SZ) will list and circulate 786.84 million restricted shares on April 23
Wanchen Group (300972.SZ) announced that the number of shares issued before the company's initial public offering has lifted sales restrictions this time...
Wanchen Group (300972.SZ) performance report: 2023 net loss of 82.965 million yuan
Gelonghui, April 15, 丨 Wanchen Group (300972.SZ) announced its 2023 annual performance report, with total operating revenue of 9.294 billion yuan, up 1,592.03% over the same period of the previous year; total profit - 84718,700 yuan, down 303.76% from the same period of the previous year; net profit attributable to shareholders of listed companies - 82.92.65 million yuan, year-on-year profit and loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 83.7569 million yuan; basic earnings per share - 0.5395 yuan.
Wanchen Group (300972.SZ) plans to promote 11.329 million restricted stock incentive plans
According to the Zhitong Finance App, Wanchen Group (300972.SZ) disclosed the 2024 Restricted Stock Incentive Plan (draft). The number of restricted shares to be awarded by the company's incentive plan is 11.329 million shares, accounting for 6.57% of the company's total share capital of 172.3932 million shares on the day the draft incentive plan was announced. Among them, the number of restricted shares granted for the first time was 10.129 million shares, and the number of restricted shares reserved was 1.2 million shares, and the grant price was 15.17 yuan/share. A total of 58 people were awarded incentives for the first time under this incentive plan.
Potential Upside For Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972) Not Without Risk
Private Companies Among Fujian Wanchen Biotechnology Group Co., Ltd.'s (SZSE:300972) Largest Stockholders and Were Hit After Last Week's 12% Price Drop
Wanchen Group (300972.SZ): The current number of SKUs is 1500~1,800
Gelonghui, January 25丨Wanchen Group (300972.SZ) recently said during a survey from institutional investors that we have always maintained a relatively fast monthly SKU iteration frequency. In order to achieve this goal, we try to introduce as many products that are not in the same category as possible, rather than just updating products. Currently, our number of SKUs is 1500 to 1,800, which accounts for a relatively low number of snack foods, and there is still plenty of room to continuously expand and iterate on new products. The company will not create its own brand in order to have its own brand. The core indicator of our product selection is whether this product is this segment
No Data